Rohan Palekar
Vorstandsvorsitzender bei 89BIO, INC.
Vermögen: 4 Mio $ am 30.04.2024
Profil
Rohan Palekar is currently the Chief Executive Officer & Director at 89bio, Inc. He is also the Chairman at Aim High For High School and an Independent Director at Neurogene, Inc. Previously, he served as the President & Chief Executive Officer at Avanir Pharmaceuticals, Inc. from 2016 to 2017.
He was also the Chief Executive Officer at Xenerex Biosciences and an Independent Director at Neoleukin Therapeutics, Inc. Additionally, he held the position of Vice President-Dermatology Sales & Marketing at Centocor, Inc. from 2001 to 2007 and Chief Commercial Officer at Medivation LLC (California) from 2008 to 2011.
Mr. Palekar completed his undergraduate and graduate studies at the University of Mumbai and holds an MBA from the Tuck School of Business at Dartmouth.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
89BIO INC
0,48% | 01.04.2024 | 459 171 ( 0,48% ) | 4 Mio $ | 30.04.2024 |
Aktive Positionen von Rohan Palekar
| Unternehmen | Position | Beginn |
|---|---|---|
| 89BIO, INC. | Vorstandsvorsitzender | 01.06.2018 |
Ehemalige bekannte Positionen von Rohan Palekar
| Unternehmen | Position | Ende |
|---|---|---|
| AVANIR PHARMACEUTICALS INC | Vorstandsvorsitzender | 31.12.2017 |
| MEDIVATION INC | Corporate Officer/Principal | 09.09.2011 |
Centocor, Inc.
 Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Vertrieb & Marketing | 01.12.2007 |
| NEUROGENE INC. | Direktor/Vorstandsmitglied | - |
Xenerex Biosciences
 Xenerex Biosciences Miscellaneous Commercial ServicesCommercial Services Xenerex Biosciences engages in developing and commercializing human antibody products to target antigens. The company was founded by John David Hansen and Wolfgang W. Scholz and is headquartered in Aliso Viejo, CA. | Vorstandsvorsitzender | - |
Ausbildung von Rohan Palekar
| University of Mumbai | Graduate Degree |
| Tuck School of Business at Dartmouth | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| 89BIO, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Medivation LLC (California)
 Medivation LLC (California) Pharmaceuticals: MajorHealth Technology Medivation LLC engages in the development and commercialization of novel therapies to treat serious diseases for which there are limited treatment options. The company was founded by Clarence Patrick Machado and David T. Hung in 2004 and is headquartered in San Francisco, CA. | Health Technology |
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Health Technology |
Avanir Pharmaceuticals, Inc.
 Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA. | Health Technology |
Xenerex Biosciences
Xenerex Biosciences Miscellaneous Commercial ServicesCommercial Services Xenerex Biosciences engages in developing and commercializing human antibody products to target antigens. The company was founded by John David Hansen and Wolfgang W. Scholz and is headquartered in Aliso Viejo, CA. | Commercial Services |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
